EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases

Details for Australian Patent Application No. 2006301579 (hide)

Owner Sanofi-Aventis

Inventors Herrmann, Matthias; Kozian, Detlef

Agent Watermark

Pub. Number AU-B-2006301579

PCT Pub. Number WO2007/042166

Priority 10 2005 048 898.6 12.10.05 DE

Filing date 30 September 2006

Wipo publication date 19 April 2007

Acceptance publication date 1 March 2012

International Classifications

C07K 14/435 (2006.01) Peptides having more than 20 amino acids - from animals

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

1 May 2008 PCT application entered the National Phase

  PCT publication WO2007/042166 Priority application(s): WO2007/042166

1 March 2012 Application Accepted

  Published as AU-B-2006301579

28 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006301582-Matrix metalloproteinase 11 vaccine

2006301578-Method for diagnosing thromboembolic disorders and coronary heart diseases